Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo and EGRIFTA

Theratechnologies (TSX:TH) is pleased to announce that it has reached a pricing agreement with the AIDS Drug Assistance Program Crisis Task Force. The agreement opens access to Trogarzo (ibalizumab-uiyk) injection and EGRIFTA^® (tesamorelin for injection) to low income, underinsured and uninsured Americans in all 50 states and the territories.

As quoted in the press release:

Trogarzo™ represents a critical new treatment advance as the first HIV therapy with a new mechanism of action approved in 10 years and proven efficacy in difficult-to-treat patients with multi-drug resistant HIV-1.

EGRIFTA^® is a growth hormone-releasing factor analog and is the only FDA-approved treatment indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

“I am very proud of the agreement we concluded with ADAP. Both Trogarzo™ and EGRIFTA^® are uniquely indicated to address important unmet medical needs of people living with HIV. We want to ensure that no one is left behind and ultimately having both products on ADAP’s formularies will go a long way towards this goal,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

Click here to read the full press release.